0000707511
false
0000707511
2023-05-09
2023-05-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2023
REGENERX BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-15070 |
|
52-1253406 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification
No.) |
15245 Shady Grove Road, Suite 470
Rockville, MD |
|
20850 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (301) 208-9191
Not Applicable
(Former name or former address, if changed since
last report.)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions: |
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Securities registered pursuant to Section 12(b) of the Act: |
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
Common |
RGRX |
OTC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item 1.01 Entry Into a Definitive Material
Agreement.
In May 2023, we made an offer
to each holder of our Series B Common Stock Purchase Warrants dated June 30, 2021 to exchange those warrants for the issuance by us of
a like number of shares of our Common Stock. Pursuant to this offer, the holders of an aggregate of 7,459,375 of these warrants agreed
to the exchange. Included among the holders participating was Mr. Finkelstein, our President and CEO (56,250 warrants) and Aptafin S.p.A.,
an affiliate of us by share ownership (1,125,000 warrants).
On July 3, 2023, we sold and
issued a $50,000 Convertible Promissory Note to Essetifin S.p.A., an affiliate of us by share ownership. This note accrues interest at
a rate of 5% per annum and is due, if not earlier converted at the option of the holder to Common Stock, on June 11, 2028. Beginning six
months after the initial note issuance, the principal and accrued interest on each note may be converted into shares of our Common Stock
based on a conversion rate of $0.02 per share, subject to customary adjustments.
To induce Essetifin S.p.A.
to lend funds to us, we also agreed to issue such investor a five-year warrant to purchase a number of shares of our Common Stock equal
to 150% of the number of shares of Common Stock into which the purchased note could initially convert. The warrant is exercisable by the
holder commencing six months after issuance at an exercise price of $0.02 per share, subject to customary adjustments.
The note and warrant we issued
are in the same forms as those described in our report on Form 8-K dated June 13, 2023.
Item 3.02 Unregistered Sales of Equity Securities.
In May and June 2023, we exchanged
an aggregate of 7,459,375 of our Series B Common Stock Purchase Warrants held by 22 individuals and entities for a like number of shares
of our Common Stock. In exchanging the warrants for shares of our Common Stock, we relied on the exemption under Section 3(a)(9) of the
Securities Act of 1933, as amended. No person or entity was paid or given any commission or other remuneration directly or indirectly
for soliciting the exchange.
On July 3, 2023, we sold to
one entity a $50,000 Convertible Promissory Note due on June 12, 2028. The principal and accrued interest on the note is convertible at
the option of the holder beginning six months after issuance into shares of our Common Stock at a rate of $0.02 per share, subject to
customary adjustments. In connection with the sale and issuance of this note, we issued this purchaser a five-year warrant to purchase
(beginning six months after issuance) an aggregate of 3,750,000 shares of our Common Stock at an exercise price of $0.02 per share, subject
to customary adjustments.
In selling and issuing the
note and warrant, we relied on the exemption under Section 4(a)(2) of the Securities Act of 1933, as amended. The securities were sold
in a private transaction to an entity that represented itself as an “accredited investor” and was acquiring the securities
for investment, and we have noted the instruments representing the securities with restrictions on transfer unless in compliance with
the Securities Act.
Item 8.01 Other Events.
On July 10, 2023, we began
distributing a letter to stockholders describing the above warrant exchange and further explaining our rationale for seeking to terminate
our reporting obligations under the Securities Exchange Act of 1934, as amended.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
|
|
|
|
REGENERX BIOPHARMACEUTICALS, INC. |
|
|
|
|
|
By: |
/s/ J.J. Finkelstein |
|
|
|
J.J. Finkelstein |
|
|
|
President and Chief Executive Officer |
|
Date: July 10, 2023.
Exhibit 10.65
|
15245 Shady Grove Road
Suite 470
Rockville, MD 20850
301.208.9191 |
July 10, 2023
Dear Stockholder:
The next few months will represent a transitional change for RegeneRx,
as we are moving from a public company to a private one and further paring down operations as we await results from our phase 3 clinical
trials in patients with neurotrophic keratitis (NK). As you know, these trials are being sponsored by our joint venture, ReGenTree, LLC
with funding from HLB Therapeutics, a Korean biopharmaceutical company. The first patient was entered in April of this year.
Many have speculated on our reasons for going private and asked questions
about the ramifications of this transition. Our reasons were simple: we were out of capital and unable to continue to fund the Company
in the current economic climate, conduct research and development or out-license or sell any potential product candidates. Moreover, the
costs of rent, legal, accounting, D&O insurance, and SEC reporting requirements, among others, are prohibitively expensive for a company
with a very small market cap and minimal cash that is solely awaiting the results of phase 3 clinical trials later this year or early
2024.
We spoke at length to investment banks, potential and existing investors,
and potential strategic partners, and concluded that the only way to keep RegeneRx operational and avoid possible bankruptcy would be
to go private. Going private, however, requires additional new capital to pay legal, accounting, and other costs, as well as funding minimal
operations for the rest of 2023 and into 2024, and we called upon management, the Board of Directors, and affiliates to contribute capital
for this purpose. Despite the significant investment risks, we were recently able to secure $225,000 of new capital from these parties.
We are open to raising additional capital from you, as an existing investor in our company, if you are interested in participating on
the same terms, as described in our SEC filings, and qualify as an “accredited investor” under federal securities laws. If
you are interested in participating before July 31, 2023, please contact us at jjfnk@regenerx.com. The minimum investment is $20,000 and
will require a letter either from your accountant or lawyer confirming your status as an “accredited investor” pursuant to
SEC regulations.
To implement our going private strategy, we will require a reverse
split of up to 1-for-100 shares of Common Stock so that we can end with fewer than 500 stockholders of record pursuant to SEC regulations
for private companies. That means that any investor holding 99 or fewer shares on June 12, 2023, will become a fractional stockholder
and will be cashed out. Remaining investors holding 100 or more shares will still hold essentially the same amount of equity in RegeneRx
as they did prior to the reverse split, albeit, without the ready ability to buy and sell RegeneRx shares in a public marketplace.
Separately, the question has also been asked as to why we offered to
exchange Series B Warrants, which were to expire in June 2026, for shares of Common Stock. Although the price of our common stock was
far below the warrants’ exercise price, the warrants had a covenant requiring that we maintain SEC registration throughout their
term. Since we made the decision to go private, RegeneRx would be in breach of the covenant and subject to potential liability. Therefore,
our only reasonable recourse was to offer to exchange, rather than exercise, the warrants for Common Stock prior to going private, which
would not require a holding period in contrast to their exercise. We believe this offered the best resolution for our company while we
await the phase 3 clinical trials results.
To show our commitment to this effort, management has not taken any
salary during 2023, and does not intend to do so for at least the balance of this year. We will endeavor to keep the Company operational
while we await data from the NK trials although it is uncertain when it will be available.
If the clinical trials are successful, it is our intent to effectively
monetize this outcome and distribute any available proceeds from product income and/or the sale of RegeneRx to stockholders on a pro rata
basis. However, it is too soon to know if or when this will happen.
We intend to maintain our web site and will update it periodically
as new information is available. We encourage stockholders to sign up to receive notice of new developments and check it periodically.
We also intend to maintain a virtual office and have email, phone, and mail service.
Thank you for your patience and we all hope for a successful conclusion.
Best
regards,
|
|
Allan L. Goldstein, Ph.D.
Chairperson |
J.J. Finkelstein
President & CEO |
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
RegeneRX Biopharmaceutic... (CE) (USOTC:RGRX)
Historical Stock Chart
From Oct 2024 to Nov 2024
RegeneRX Biopharmaceutic... (CE) (USOTC:RGRX)
Historical Stock Chart
From Nov 2023 to Nov 2024